O	0	10	Discussion	Discussion	NN	B-NP

O	11	13	In	In	IN	B-PP
O	14	17	our	our	PRP$	B-NP
O	18	26	previous	previous	JJ	I-NP
O	27	31	work	work	NN	I-NP
O	31	32	,	,	,	O
O	33	35	we	we	PRP	B-NP
O	36	46	considered	consider	VBD	B-VP
O	47	49	in	in	IN	B-PP
O	50	52	CD	CD	NNP	B-NP
O	53	61	families	family	VBZ	B-VP
O	62	65	the	the	DT	B-NP
O	66	70	risk	risk	NN	I-NP
O	71	73	to	to	TO	B-VP
O	74	81	develop	develop	VB	I-VP
O	82	85	the	the	DT	B-NP
O	86	93	disease	disease	NN	I-NP
O	94	103	according	accord	VBG	B-PP
O	104	106	to	to	TO	B-PP
O	107	108	a	a	DT	B-NP
O	109	117	specific	specific	JJ	I-NP
O	118	121	HLA	HLA	NN	I-NP
O	122	132	haplotypes	haplotype	NNS	I-NP
O	132	133	,	,	,	O
O	134	143	obtaining	obtain	VBG	B-VP
O	144	145	a	a	DT	B-NP
O	146	150	risk	risk	NN	I-NP
O	151	156	range	range	NN	I-NP
O	157	161	from	from	IN	B-PP
O	162	163	0	0	CD	B-NP
O	163	164	.	.	.	O
O	164	166	01	01	CD	B-NP
O	167	169	to	to	TO	B-PP
O	170	171	>	>	SYM	B-NP
O	171	172	=	=	SYM	B-VP
O	172	173	0	0	CD	B-NP
O	173	174	.	.	SYM	I-NP
O	174	176	20	20	CD	I-NP
O	177	178	[	[	(	I-NP
O	178	179	1	1	CD	I-NP
O	179	180	]	]	)	O
O	180	181	.	.	.	O

O	182	184	In	In	IN	B-PP
O	185	188	the	the	DT	B-NP
O	189	196	present	present	JJ	I-NP
O	197	202	study	study	NN	I-NP
O	203	205	we	we	PRP	B-NP
O	206	215	evaluated	evaluate	VBD	B-VP
O	216	219	the	the	DT	B-NP
O	220	224	role	role	NN	I-NP
O	225	227	of	of	IN	B-PP
O	228	229	3	3	CD	B-NP
O	230	233	non	non	AFX	I-NP
O	233	234	-	-	HYPH	I-NP
O	234	237	HLA	HLA	NN	I-NP
O	238	245	genetic	genetic	JJ	I-NP
O	246	253	markers	marker	NNS	I-NP
O	254	256	to	to	TO	B-VP
O	257	266	influence	influence	VB	I-VP
O	267	270	the	the	DT	B-NP
O	271	273	CD	CD	NNP	I-NP
O	274	278	risk	risk	NN	I-NP
O	279	281	in	in	IN	B-PP
O	282	287	first	first	JJ	B-NP
O	288	297	relatives	relative	NNS	I-NP
O	298	300	of	of	IN	B-PP
O	301	303	CD	CD	NNP	B-NP
O	304	312	affected	affect	VBN	I-NP
O	313	321	children	child	NNS	I-NP
O	321	322	.	.	.	O

O	323	325	We	We	PRP	B-NP
O	326	335	collected	collect	VBD	B-VP
O	336	340	data	datum	NNS	B-NP
O	341	343	on	on	IN	B-PP
O	344	352	families	family	NNS	B-NP
O	353	357	with	with	IN	B-PP
O	358	360	at	at	IN	B-NP
O	361	366	least	least	JJS	I-NP
O	367	370	one	one	CD	I-NP
O	371	373	CD	CD	NN	I-NP
O	373	374	-	-	HYPH	B-VP
O	374	382	affected	affect	VBN	I-VP
O	383	388	among	among	IN	B-PP
O	389	398	offspring	offspring	NN	B-NP
O	398	399	.	.	.	O

O	400	404	This	This	DT	B-NP
O	405	411	family	family	NN	I-NP
O	412	415	set	set	NN	I-NP
O	416	422	helped	help	VBD	B-VP
O	423	425	to	to	TO	I-VP
O	426	434	evaluate	evaluate	VB	I-VP
O	435	438	the	the	DT	B-NP
O	439	450	association	association	NN	I-NP
O	451	458	between	between	IN	B-PP
O	459	463	SNPs	SNP	NNS	B-NP
O	464	467	and	and	CC	O
O	468	470	CD	CD	NN	B-NP
O	471	472	(	(	(	O
O	472	475	TDT	TDT	NN	B-NP
O	476	478	on	on	IN	B-PP
O	479	486	parents	parent	NNS	B-NP
O	486	487	-	-	HYPH	O
O	487	496	offspring	offspre	VBG	B-VP
O	497	502	trios	trio	NNS	B-NP
O	502	503	)	)	)	O
O	504	507	and	and	CC	O
O	508	510	to	to	TO	B-VP
O	511	519	estimate	estimate	VB	I-VP
O	520	523	the	the	DT	B-NP
O	524	528	risk	risk	NN	I-NP
O	529	531	of	of	IN	B-PP
O	532	534	CD	CD	NN	B-NP
O	535	537	in	in	IN	B-PP
O	538	541	the	the	DT	B-NP
O	542	547	other	other	JJ	I-NP
O	548	552	sibs	sib	NNS	I-NP
O	552	553	.	.	.	O

O	554	557	The	The	DT	B-NP
O	558	561	TDT	TDT	NN	I-NP
O	562	568	design	design	NN	I-NP
O	569	577	provides	provide	VBZ	B-VP
O	578	588	robustness	robustness	NN	B-NP
O	589	591	to	to	TO	B-PP
O	592	602	population	population	NN	B-NP
O	603	617	stratification	stratification	NN	I-NP
O	618	621	and	and	CC	I-NP
O	622	632	mitigation	mitigation	NN	I-NP
O	633	635	of	of	IN	B-PP
O	636	639	the	the	DT	B-NP
O	640	648	possible	possible	JJ	I-NP
O	649	660	confounding	confound	VBG	I-NP
O	661	667	effect	effect	NN	I-NP
O	668	670	of	of	IN	B-PP
O	671	684	environmental	environmental	JJ	B-NP
O	685	692	factors	factor	NNS	I-NP
O	692	693	,	,	,	O
O	694	701	because	because	IN	B-SBAR
O	702	705	all	all	DT	B-NP
O	706	712	family	family	NN	I-NP
O	713	720	members	member	NNS	I-NP
O	721	726	share	share	VBP	B-VP
O	727	730	the	the	DT	B-NP
O	731	735	same	same	JJ	I-NP
O	736	747	environment	environment	NN	I-NP
O	748	749	[	[	(	O
O	749	751	16	16	CD	B-NP
O	751	752	]	]	)	O
O	752	753	.	.	.	O

O	754	757	Ten	Ten	CD	B-NP
O	758	762	SNPs	SNP	NNS	I-NP
O	762	763	,	,	,	O
O	764	772	selected	select	VBN	B-VP
O	773	777	from	from	IN	B-PP
O	778	783	those	those	DT	B-NP
O	784	794	previously	previously	RB	B-VP
O	795	800	found	find	VBN	I-VP
O	801	803	to	to	TO	I-VP
O	804	806	be	be	VB	I-VP
O	807	817	associated	associate	VBN	I-VP
O	818	822	with	with	IN	B-PP
O	823	825	CD	CD	NN	B-NP
O	826	828	by	by	IN	B-PP
O	829	833	GWAS	GWAS	NN	B-NP
O	834	835	[	[	(	O
O	835	837	13	13	CD	B-NP
O	837	838	]	]	)	O
O	838	839	,	,	,	O
O	840	844	were	be	VBD	B-VP
O	845	857	successfully	successfully	RB	I-VP
O	858	867	genotyped	genotype	VBN	I-VP
O	867	868	.	.	.	O

O	869	871	In	In	IN	B-PP
O	872	875	our	our	PRP$	B-NP
O	876	886	population	population	NN	I-NP
O	887	892	three	three	CD	B-NP
O	893	897	SNPs	SNP	NNS	I-NP
O	898	906	resulted	result	VBD	B-VP
O	907	920	significantly	significantly	RB	I-VP
O	921	931	associated	associate	VBN	I-VP
O	932	936	with	with	IN	B-PP
O	937	939	CD	CD	NN	B-NP
O	940	941	(	(	(	O
O	941	946	those	those	DT	B-NP
O	947	949	in	in	IN	B-PP
O	950	953	LPP	LPP	NN	B-NP
O	953	954	,	,	,	I-NP
O	955	959	RGS1	RGS1	NN	I-NP
O	960	963	and	and	CC	I-NP
O	964	967	REL	REL	NN	I-NP
O	968	973	genes	gene	NNS	I-NP
O	973	974	)	)	)	O
O	975	978	and	and	CC	O
O	979	982	the	the	DT	B-NP
O	983	988	other	other	JJ	I-NP
O	989	994	seven	seven	CD	I-NP
O	995	1007	investigated	investigate	VBN	I-NP
O	1008	1012	SNPs	SNP	NNS	I-NP
O	1012	1013	,	,	,	O
O	1014	1018	even	even	RB	B-SBAR
O	1019	1021	if	if	IN	I-SBAR
O	1022	1025	not	not	RB	B-VP
O	1026	1039	statistically	statistically	RB	I-VP
O	1040	1050	associated	associate	VBN	I-VP
O	1051	1055	with	with	IN	B-PP
O	1056	1058	CD	CD	NNP	B-NP
O	1058	1059	,	,	,	O
O	1060	1066	showed	show	VBD	B-VP
O	1067	1073	always	always	RB	B-ADVP
O	1074	1076	an	an	DT	B-NP
O	1077	1083	higher	high	JJR	I-NP
O	1084	1093	frequency	frequency	NN	I-NP
O	1094	1096	of	of	IN	B-PP
O	1097	1100	the	the	DT	B-NP
O	1101	1111	previously	previously	RB	I-NP
O	1112	1120	reported	report	VBN	I-NP
O	1121	1125	risk	risk	NN	I-NP
O	1126	1133	alleles	allele	NNS	I-NP
O	1134	1135	[	[	(	O
O	1135	1137	13	13	CD	B-NP
O	1137	1138	]	]	)	O
O	1139	1141	in	in	IN	B-PP
O	1142	1150	affected	affected	JJ	B-NP
O	1151	1159	subjects	subject	NNS	I-NP
O	1160	1164	than	than	IN	B-PP
O	1165	1167	in	in	IN	B-PP
O	1168	1176	controls	control	NNS	B-NP
O	1176	1177	.	.	.	O

O	1178	1181	The	The	DT	B-NP
O	1182	1187	three	three	CD	I-NP
O	1188	1193	genes	gene	NNS	I-NP
O	1194	1202	selected	select	VBN	B-VP
O	1203	1209	appear	appear	VBP	B-VP
O	1210	1212	to	to	TO	I-VP
O	1213	1215	be	be	VB	I-VP
O	1216	1225	appealing	appeal	VBG	I-VP
O	1226	1229	for	for	IN	B-PP
O	1230	1233	the	the	DT	B-NP
O	1234	1246	pathogenesis	pathogenesis	NN	I-NP
O	1247	1249	of	of	IN	B-PP
O	1250	1252	CD	CD	NNP	B-NP
O	1252	1253	.	.	.	O

O	1254	1257	LPP	LPP	NN	B-NP
O	1258	1259	(	(	(	O
O	1259	1261	OR	OR	NN	B-NP
O	1262	1263	=	=	SYM	B-VP
O	1264	1265	2	2	CD	B-NP
O	1265	1266	.	.	.	O
O	1266	1268	36	36	CD	B-NP
O	1268	1269	;	;	:	O
O	1270	1271	p	p	NN	B-NP
O	1271	1272	<	<	SYM	B-ADJP
O	1272	1273	0	0	CD	B-NP
O	1273	1274	.	.	.	I-NP
O	1274	1277	001	001	CD	I-NP
O	1277	1278	)	)	)	O
O	1279	1282	was	be	VBD	B-VP
O	1283	1291	reported	report	VBN	I-VP
O	1292	1294	to	to	TO	I-VP
O	1295	1297	be	be	VB	I-VP
O	1298	1304	highly	highly	RB	I-VP
O	1305	1314	expressed	express	VBN	I-VP
O	1315	1317	in	in	IN	B-PP
B-Multi-tissue_structure	1318	1323	small	small	JJ	B-NP
I-Multi-tissue_structure	1324	1334	intestinal	intestinal	JJ	I-NP
I-Multi-tissue_structure	1335	1341	mucosa	mucosa	NN	I-NP
O	1342	1345	and	and	CC	O
O	1346	1349	may	may	MD	B-VP
O	1350	1354	have	have	VB	I-VP
O	1355	1356	a	a	DT	B-NP
O	1357	1367	structural	structural	JJ	I-NP
O	1368	1372	role	role	NN	I-NP
O	1373	1375	at	at	IN	B-PP
B-Cellular_component	1376	1381	sites	site	NNS	B-NP
O	1382	1384	of	of	IN	B-PP
B-Cell	1385	1389	cell	cell	NN	B-NP
O	1390	1398	adhesion	adhesion	NN	I-NP
O	1399	1401	in	in	IN	B-PP
O	1402	1413	maintaining	maintain	VBG	B-VP
B-Cell	1414	1418	cell	cell	NN	B-NP
O	1419	1424	shape	shape	NN	I-NP
O	1425	1428	and	and	CC	O
O	1429	1437	motility	motility	NN	B-NP
O	1438	1439	[	[	(	O
O	1439	1440	7	7	CD	B-NP
O	1440	1441	]	]	)	O
O	1441	1442	.	.	.	O

O	1443	1447	RGS1	RGS1	NN	B-NP
O	1448	1449	(	(	(	O
O	1449	1451	OR	OR	NN	B-NP
O	1452	1453	=	=	SYM	B-VP
O	1454	1455	1	1	CD	B-NP
O	1455	1456	.	.	.	O
O	1456	1458	75	75	CD	B-NP
O	1458	1459	;	;	:	O
O	1460	1461	p	p	NN	B-NP
O	1462	1463	=	=	SYM	B-VP
O	1464	1465	0	0	CD	B-NP
O	1465	1466	.	.	SYM	I-NP
O	1466	1469	025	025	CD	I-NP
O	1469	1470	)	)	)	O
O	1471	1478	belongs	belong	VBZ	B-VP
O	1479	1481	to	to	TO	B-PP
O	1482	1483	a	a	DT	B-NP
O	1484	1490	family	family	NN	I-NP
O	1491	1493	of	of	IN	B-PP
O	1494	1497	RGS	RGS	NN	B-NP
O	1498	1503	genes	gene	NNS	I-NP
O	1503	1504	.	.	.	O

O	1505	1507	It	It	PRP	B-NP
O	1508	1518	attenuates	attenuate	VBZ	B-VP
O	1519	1522	the	the	DT	B-NP
O	1523	1532	signaling	signaling	NN	I-NP
O	1533	1541	activity	activity	NN	I-NP
O	1542	1544	of	of	IN	B-PP
O	1545	1546	G	G	NN	B-NP
O	1546	1547	-	-	HYPH	B-NP
O	1547	1555	proteins	protein	NNS	I-NP
O	1555	1556	,	,	,	O
O	1557	1565	blocking	block	VBG	B-VP
O	1566	1569	the	the	DT	B-NP
O	1570	1576	homing	homing	NN	I-NP
O	1577	1579	of	of	IN	B-PP
B-Cell	1580	1585	Intra	Intra	NNP	B-NP
I-Cell	1586	1596	Epithelial	Epithelial	NNP	I-NP
I-Cell	1597	1608	Lymphocytes	Lymphocytes	NNP	I-NP
O	1609	1610	(	(	(	O
B-Cell	1610	1614	IELs	IEL	NNS	B-NP
O	1614	1615	)	)	)	O
O	1615	1616	,	,	,	O
O	1617	1620	and	and	CC	O
O	1621	1623	it	it	PRP	B-NP
O	1624	1626	is	be	VBZ	B-VP
O	1627	1639	specifically	specifically	RB	I-VP
O	1640	1649	expressed	express	VBN	I-VP
O	1650	1654	both	both	CC	O
O	1655	1657	in	in	IN	B-PP
O	1658	1663	human	human	JJ	B-NP
B-Multi-tissue_structure	1664	1669	small	small	JJ	I-NP
I-Multi-tissue_structure	1670	1680	intestinal	intestinal	JJ	I-NP
I-Multi-tissue_structure	1681	1687	mucosa	mucosa	NN	I-NP
O	1688	1691	and	and	CC	B-PP
O	1692	1694	in	in	IN	B-PP
O	1695	1701	murine	murine	JJ	B-NP
B-Cell	1702	1706	IELs	IEL	NNS	I-NP
O	1706	1707	,	,	,	O
O	1708	1711	key	key	JJ	B-NP
O	1712	1719	players	player	NNS	I-NP
O	1720	1722	in	in	IN	B-PP
O	1723	1726	the	the	DT	B-NP
O	1727	1738	development	development	NN	I-NP
O	1739	1741	of	of	IN	B-PP
O	1742	1747	human	human	JJ	B-NP
O	1748	1750	CD	CD	NN	I-NP
O	1751	1758	villous	villous	JJ	I-NP
O	1759	1766	atrophy	atrophy	NN	I-NP
O	1767	1768	[	[	(	O
O	1768	1769	7	7	CD	B-NP
O	1769	1770	]	]	)	O
O	1770	1771	,	,	,	O
O	1772	1773	[	[	(	O
O	1773	1775	17	17	CD	B-NP
O	1775	1776	]	]	)	O
O	1776	1777	.	.	.	O

O	1778	1781	REL	REL	NN	B-NP
O	1782	1783	(	(	(	O
O	1783	1785	OR	OR	NN	B-NP
O	1786	1787	=	=	SYM	B-VP
O	1788	1789	1	1	CD	B-NP
O	1789	1790	.	.	.	I-NP
O	1790	1792	66	66	CD	I-NP
O	1792	1793	;	;	:	O
O	1794	1795	p	p	NN	B-NP
O	1796	1797	=	=	SYM	B-VP
O	1798	1799	0	0	CD	B-NP
O	1799	1800	.	.	SYM	I-NP
O	1800	1803	034	034	CD	I-NP
O	1803	1804	)	)	)	O
O	1805	1807	is	be	VBZ	B-VP
O	1808	1809	a	a	DT	B-NP
O	1810	1817	subunit	subunit	NN	I-NP
O	1818	1820	of	of	IN	B-PP
O	1821	1823	NF	NF	NN	B-NP
O	1823	1824	-	-	HYPH	B-NP
O	1824	1826	kB	kB	NN	I-NP
O	1827	1834	complex	complex	NN	I-NP
O	1834	1835	,	,	,	O
O	1836	1846	implicated	implicate	VBN	B-VP
O	1847	1849	in	in	IN	B-PP
B-Cell	1850	1851	T	T	NN	B-NP
I-Cell	1852	1856	cell	cell	NN	I-NP
O	1857	1872	differentiation	differentiation	NN	I-NP
O	1873	1874	[	[	(	O
O	1874	1876	18	18	CD	B-NP
O	1876	1877	]	]	)	O
O	1878	1881	and	and	CC	O
O	1882	1884	it	it	PRP	B-NP
O	1885	1892	appears	appear	VBZ	B-VP
O	1893	1895	to	to	TO	I-VP
O	1896	1898	be	be	VB	I-VP
O	1899	1900	a	a	DT	B-NP
O	1901	1904	key	key	JJ	I-NP
O	1905	1913	molecule	molecule	NN	I-NP
O	1914	1924	regulating	regulate	VBG	B-VP
O	1925	1937	inflammation	inflammation	NN	B-NP
O	1938	1941	and	and	CC	O
O	1942	1945	the	the	DT	B-NP
O	1946	1952	switch	switch	NN	I-NP
O	1953	1957	from	from	IN	B-PP
O	1958	1967	tolerance	tolerance	NN	B-NP
O	1968	1970	to	to	TO	B-PP
O	1971	1983	autoimmunity	autoimmunity	NN	B-NP
O	1984	1985	[	[	(	O
O	1985	1987	19	19	CD	B-NP
O	1987	1988	]	]	)	O
O	1988	1989	.	.	.	O

O	1990	1992	It	It	PRP	B-NP
O	1993	1995	is	be	VBZ	B-VP
O	1996	2007	interesting	interesting	JJ	B-ADJP
O	2008	2010	to	to	TO	B-VP
O	2011	2015	note	note	VB	I-VP
O	2016	2020	that	that	IN	B-SBAR
O	2021	2024	our	our	PRP$	B-NP
O	2025	2029	data	datum	NNS	I-NP
O	2030	2037	confirm	confirm	VBP	B-VP
O	2038	2046	previous	previous	JJ	B-NP
O	2047	2059	pathogenetic	pathogenetic	JJ	I-NP
O	2060	2072	implications	implication	NNS	I-NP
O	2073	2081	reported	report	VBN	B-VP
O	2082	2084	in	in	IN	B-PP
O	2085	2095	literature	literature	NN	B-NP
O	2096	2098	of	of	IN	B-PP
O	2099	2104	these	these	DT	B-NP
O	2105	2109	SNPs	SNP	NNS	I-NP
O	2110	2114	with	with	IN	B-PP
O	2115	2117	CD	CD	NN	B-NP
O	2118	2120	as	as	RB	B-CONJP
O	2121	2125	well	well	RB	I-CONJP
O	2126	2128	as	as	IN	I-CONJP
O	2129	2133	with	with	IN	B-PP
O	2134	2139	other	other	JJ	B-NP
O	2140	2150	autoimmune	autoimmune	JJ	I-NP
O	2151	2159	diseases	disease	NNS	I-NP
O	2160	2161	[	[	(	O
O	2161	2163	20	20	CD	B-NP
O	2163	2164	]	]	)	O
O	2164	2165	.	.	.	O

O	2166	2168	By	By	IN	B-PP
O	2169	2172	the	the	DT	B-NP
O	2173	2181	Bayesian	Bayesian	JJ	I-NP
O	2182	2190	approach	approach	NN	I-NP
O	2191	2193	we	we	PRP	B-NP
O	2194	2204	calculated	calculate	VBD	B-VP
O	2205	2206	a	a	DT	B-NP
O	2207	2214	ranking	ranking	JJ	I-NP
O	2215	2220	score	score	NN	I-NP
O	2221	2222	(	(	(	O
O	2222	2224	BS	BS	NN	B-NP
O	2224	2225	)	)	)	O
O	2226	2231	among	among	IN	B-PP
O	2232	2235	the	the	DT	B-NP
O	2236	2240	sibs	sib	NNS	I-NP
O	2240	2241	.	.	.	O

O	2242	2249	However	However	RB	B-ADVP
O	2249	2250	,	,	,	O
O	2251	2253	it	it	PRP	B-NP
O	2254	2260	should	should	MD	B-VP
O	2261	2263	be	be	VB	I-VP
O	2264	2274	considered	consider	VBN	I-VP
O	2275	2279	that	that	IN	B-SBAR
O	2280	2282	BS	BS	NNP	B-NP
O	2283	2285	is	be	VBZ	B-VP
O	2286	2289	not	not	RB	O
O	2290	2291	a	a	DT	B-NP
O	2292	2297	plain	plain	JJ	I-NP
O	2298	2305	disease	disease	NN	I-NP
O	2306	2310	risk	risk	NN	I-NP
O	2310	2311	,	,	,	O
O	2312	2318	rather	rather	RB	B-ADVP
O	2319	2320	a	a	DT	B-NP
O	2321	2327	method	method	NN	I-NP
O	2328	2330	to	to	TO	B-VP
O	2331	2335	rank	rank	VB	I-VP
O	2336	2345	different	different	JJ	B-NP
O	2346	2355	genotypes	genotype	NNS	I-NP
O	2356	2365	according	accord	VBG	B-PP
O	2366	2368	to	to	TO	B-PP
O	2369	2374	their	their	PRP$	B-NP
O	2375	2387	contribution	contribution	NN	I-NP
O	2388	2390	to	to	TO	B-VP
O	2391	2395	make	make	VB	I-VP
O	2396	2398	an	an	DT	B-NP
O	2399	2409	individual	individual	JJ	I-NP
O	2410	2421	susceptible	susceptible	JJ	B-ADJP
O	2422	2424	to	to	TO	B-PP
O	2425	2427	CD	CD	NNP	B-NP
O	2427	2428	.	.	.	O

O	2429	2432	For	For	IN	B-PP
O	2433	2441	instance	instance	NN	B-NP
O	2441	2442	,	,	,	O
O	2443	2447	some	some	DT	B-NP
O	2448	2450	of	of	IN	B-PP
O	2451	2454	our	our	PRP$	B-NP
O	2455	2457	BS	BS	NNS	I-NP
O	2458	2461	are	be	VBP	B-VP
O	2462	2466	very	very	RB	B-ADJP
O	2467	2471	near	near	JJ	I-ADJP
O	2472	2474	to	to	TO	B-PP
O	2475	2476	1	1	CD	B-NP
O	2476	2477	,	,	,	O
O	2478	2490	nevertheless	nevertheless	RB	B-ADVP
O	2491	2495	none	none	NN	B-NP
O	2496	2498	of	of	IN	B-PP
O	2499	2502	the	the	DT	B-NP
O	2503	2513	considered	consider	VBN	I-NP
O	2514	2523	genotypes	genotype	NNS	I-NP
O	2524	2529	could	could	MD	B-VP
O	2530	2534	give	give	VB	I-VP
O	2535	2536	a	a	DT	B-NP
O	2537	2540	100	100	CD	I-NP
O	2540	2541	%	%	NN	I-NP
O	2542	2546	risk	risk	NN	I-NP
O	2547	2549	to	to	TO	B-VP
O	2550	2557	develop	develop	VB	I-VP
O	2558	2561	the	the	DT	B-NP
O	2562	2569	disease	disease	NN	I-NP
O	2569	2570	.	.	.	O

O	2571	2573	In	In	IN	B-PP
O	2574	2579	other	other	JJ	B-NP
O	2580	2585	terms	term	NNS	I-NP
O	2585	2586	,	,	,	O
O	2587	2589	we	we	PRP	B-NP
O	2590	2600	considered	consider	VBD	B-VP
O	2601	2604	the	the	DT	B-NP
O	2605	2607	BS	BS	NNP	I-NP
O	2608	2610	as	as	IN	B-PP
O	2611	2612	a	a	DT	B-NP
O	2613	2620	ranking	ranking	JJ	I-NP
O	2621	2628	measure	measure	NN	I-NP
O	2628	2629	,	,	,	O
O	2630	2634	only	only	RB	B-ADVP
O	2635	2642	stating	state	VBG	B-VP
O	2643	2647	that	that	IN	B-SBAR
O	2648	2649	a	a	DT	B-NP
O	2650	2655	given	give	VBN	I-NP
O	2656	2664	genotype	genotype	NN	I-NP
O	2665	2670	could	could	MD	B-VP
O	2671	2677	assign	assign	VB	I-VP
O	2678	2679	a	a	DT	B-NP
O	2680	2686	higher	high	JJR	I-NP
O	2687	2691	risk	risk	NN	I-NP
O	2692	2696	than	than	IN	B-PP
O	2697	2704	another	another	DT	B-NP
O	2705	2713	genotype	genotype	NN	I-NP
O	2714	2717	but	but	CC	O
O	2718	2722	does	do	VBZ	B-VP
O	2723	2726	not	not	RB	I-VP
O	2727	2732	allow	allow	VB	I-VP
O	2733	2734	a	a	DT	B-NP
O	2735	2747	quantitative	quantitative	JJ	I-NP
O	2748	2755	measure	measure	NN	I-NP
O	2756	2758	of	of	IN	B-PP
O	2759	2762	the	the	DT	B-NP
O	2763	2767	risk	risk	NN	I-NP
O	2768	2778	difference	difference	NN	I-NP
O	2779	2780	(	(	(	O
O	2780	2781	2	2	CD	B-NP
O	2781	2782	-	-	HYPH	O
O	2782	2786	fold	fold	RB	B-ADVP
O	2786	2787	,	,	,	O
O	2788	2789	3	3	CD	B-NP
O	2789	2790	-	-	HYPH	O
O	2790	2794	fold	fold	RB	B-ADVP
O	2794	2795	,	,	,	O
O	2796	2799	etc	etc	NN	B-NP
O	2799	2800	)	)	)	O
O	2800	2801	.	.	.	O

O	2802	2809	However	However	RB	B-ADVP
O	2809	2810	,	,	,	O
O	2811	2815	even	even	RB	B-SBAR
O	2816	2818	if	if	IN	I-SBAR
O	2819	2822	the	the	DT	B-NP
O	2823	2831	addition	addition	NN	I-NP
O	2832	2834	of	of	IN	B-PP
O	2835	2839	only	only	RB	B-NP
O	2840	2841	3	3	CD	I-NP
O	2842	2846	SNPs	SNP	NNS	I-NP
O	2847	2849	to	to	TO	B-PP
O	2850	2853	HLA	HLA	NN	B-NP
O	2854	2859	could	could	MD	B-VP
O	2860	2862	be	be	VB	I-VP
O	2863	2873	considered	consider	VBN	I-VP
O	2874	2876	at	at	IN	B-PP
O	2877	2878	"	"	``	O
O	2878	2883	minor	minor	JJ	B-NP
O	2884	2890	effect	effect	NN	I-NP
O	2890	2891	"	"	''	O
O	2892	2893	[	[	(	O
O	2893	2895	13	13	CD	B-NP
O	2895	2896	]	]	)	O
O	2896	2897	,	,	,	O
O	2898	2900	we	we	PRP	B-NP
O	2901	2913	demonstrated	demonstrate	VBD	B-VP
O	2914	2918	that	that	IN	B-SBAR
O	2919	2923	they	they	PRP	B-NP
O	2924	2929	could	could	MD	B-VP
O	2930	2943	significantly	significantly	RB	I-VP
O	2944	2951	improve	improve	VB	I-VP
O	2952	2955	the	the	DT	B-NP
O	2956	2966	prediction	prediction	NN	I-NP
O	2967	2969	of	of	IN	B-PP
O	2970	2972	CD	CD	NN	B-NP
O	2973	2977	risk	risk	NN	I-NP
O	2978	2980	in	in	IN	B-PP
O	2981	2985	sibs	sib	NNS	B-NP
O	2985	2986	,	,	,	O
O	2987	2989	in	in	IN	B-PP
O	2990	2995	terms	term	NNS	B-NP
O	2996	2998	of	of	IN	B-PP
O	2999	3009	diagnostic	diagnostic	JJ	B-NP
O	3010	3021	sensitivity	sensitivity	NN	I-NP
O	3022	3025	and	and	CC	O
O	3026	3034	negative	negative	JJ	B-NP
O	3035	3045	predictive	predictive	JJ	I-NP
O	3046	3051	value	value	NN	I-NP
O	3051	3052	.	.	.	O

O	3053	3055	So	So	RB	B-ADVP
O	3055	3056	,	,	,	O
O	3057	3059	in	in	IN	B-PP
O	3060	3061	a	a	DT	B-NP
O	3062	3068	cohort	cohort	NN	I-NP
O	3069	3071	of	of	IN	B-PP
O	3072	3074	CD	CD	NN	B-NP
O	3075	3083	families	family	NNS	I-NP
O	3083	3084	,	,	,	O
O	3085	3088	our	our	PRP$	B-NP
O	3089	3093	data	datum	NNS	I-NP
O	3094	3101	confirm	confirm	VBP	B-VP
O	3102	3106	that	that	IN	B-SBAR
O	3107	3110	non	non	AFX	B-NP
O	3110	3111	-	-	HYPH	I-NP
O	3111	3114	HLA	HLA	NN	I-NP
O	3115	3119	SNPs	SNP	NNS	I-NP
O	3120	3130	evaluation	evaluation	NN	I-NP
O	3131	3133	is	be	VBZ	B-VP
O	3134	3136	an	an	DT	B-NP
O	3137	3144	usefull	usefull	JJ	I-NP
O	3145	3155	diagnostic	diagnostic	JJ	I-NP
O	3156	3160	tool	tool	NN	I-NP
O	3161	3163	in	in	IN	B-PP
O	3164	3166	CD	CD	NN	B-NP
O	3167	3171	risk	risk	NN	I-NP
O	3172	3182	evaluation	evaluation	NN	I-NP
O	3183	3185	as	as	IN	B-PP
O	3186	3187	a	a	DT	B-NP
O	3188	3196	previous	previous	JJ	I-NP
O	3197	3202	study	study	NN	I-NP
O	3203	3209	showed	show	VBD	B-VP
O	3210	3212	in	in	IN	B-PP
O	3213	3215	CD	CD	NN	B-NP
O	3216	3225	unrelated	unrelated	JJ	I-NP
O	3226	3234	subjects	subject	NNS	I-NP
O	3235	3236	[	[	(	O
O	3236	3238	14	14	CD	B-NP
O	3238	3239	]	]	)	O
O	3239	3240	.	.	.	O

O	3241	3243	CD	CD	NNP	B-NP
O	3243	3244	,	,	,	O
O	3245	3247	on	on	IN	B-PP
O	3248	3251	the	the	DT	B-NP
O	3252	3257	basis	basis	NN	I-NP
O	3258	3260	of	of	IN	B-PP
O	3261	3264	the	the	DT	B-NP
O	3265	3271	actual	actual	JJ	I-NP
O	3272	3281	knowledge	knowledge	NN	I-NP
O	3281	3282	,	,	,	O
O	3283	3289	cannot	cannot	MD	B-VP
O	3290	3292	be	be	VB	I-VP
O	3293	3300	exactly	exactly	RB	I-VP
O	3301	3310	predicted	predict	VBN	I-VP
O	3311	3313	by	by	IN	B-PP
O	3314	3321	genetic	genetic	JJ	B-NP
O	3322	3329	testing	testing	NN	I-NP
O	3329	3330	,	,	,	O
O	3331	3334	but	but	CC	O
O	3335	3336	a	a	DT	B-NP
O	3337	3345	reliable	reliable	JJ	I-NP
O	3346	3359	probabilistic	probabilistic	JJ	I-NP
O	3360	3366	method	method	NN	I-NP
O	3367	3372	might	might	MD	B-VP
O	3373	3375	be	be	VB	I-VP
O	3376	3386	associated	associate	VBN	I-VP
O	3387	3389	to	to	TO	B-PP
O	3390	3397	careful	careful	JJ	B-NP
O	3398	3410	surveillance	surveillance	NN	I-NP
O	3411	3413	of	of	IN	B-PP
O	3414	3421	infants	infant	NNS	B-NP
O	3422	3430	carrying	carry	VBG	B-VP
O	3431	3434	the	the	DT	B-NP
O	3435	3441	higher	high	JJR	I-NP
O	3442	3446	risk	risk	NN	I-NP
O	3446	3447	.	.	.	O

O	3448	3452	This	This	DT	B-NP
O	3453	3457	will	will	MD	B-VP
O	3458	3462	help	help	VB	I-VP
O	3463	3465	to	to	TO	I-VP
O	3466	3479	significantly	significantly	RB	I-VP
O	3480	3486	reduce	reduce	VB	I-VP
O	3487	3490	the	the	DT	B-NP
O	3491	3496	heavy	heavy	JJ	I-NP
O	3497	3501	load	load	NN	I-NP
O	3502	3504	of	of	IN	B-PP
O	3505	3512	anxiety	anxiety	NN	B-NP
O	3513	3516	and	and	CC	I-NP
O	3517	3521	pain	pain	NN	I-NP
O	3522	3532	associated	associate	VBN	B-VP
O	3533	3537	with	with	IN	B-PP
O	3538	3541	the	the	DT	B-NP
O	3542	3552	appearance	appearance	NN	I-NP
O	3553	3555	of	of	IN	B-PP
O	3556	3564	symptoms	symptom	NNS	B-NP
O	3565	3567	of	of	IN	B-PP
O	3568	3570	CD	CD	NNP	B-NP
O	3570	3571	,	,	,	O
O	3572	3574	by	by	IN	B-PP
O	3575	3587	anticipating	anticipate	VBG	B-VP
O	3587	3588	,	,	,	O
O	3589	3593	with	with	IN	B-PP
O	3594	3600	simple	simple	JJ	B-NP
O	3601	3612	serological	serological	JJ	I-NP
O	3613	3618	tests	test	NNS	I-NP
O	3618	3619	,	,	,	O
O	3620	3623	the	the	DT	B-NP
O	3624	3632	clinical	clinical	JJ	I-NP
O	3633	3643	appearance	appearance	NN	I-NP
O	3644	3646	of	of	IN	B-PP
O	3647	3650	the	the	DT	B-NP
O	3651	3658	disease	disease	NN	I-NP
O	3658	3659	.	.	.	O

O	3660	3662	To	To	TO	B-VP
O	3663	3670	improve	improve	VB	I-VP
O	3671	3674	the	the	DT	B-NP
O	3675	3686	possibility	possibility	NN	I-NP
O	3687	3689	to	to	TO	B-VP
O	3690	3698	identify	identify	VB	I-VP
O	3699	3703	high	high	JJ	B-NP
O	3704	3708	risk	risk	NN	I-NP
O	3709	3717	patients	patient	NNS	I-NP
O	3718	3720	in	in	IN	B-PP
O	3721	3723	CD	CD	NN	B-NP
O	3724	3732	families	family	NNS	I-NP
O	3733	3735	we	we	PRP	B-NP
O	3736	3743	propose	propose	VBP	B-VP
O	3744	3746	in	in	IN	B-PP
O	3747	3758	alternative	alternative	JJ	B-NP
O	3759	3761	to	to	TO	B-PP
O	3762	3765	the	the	DT	B-NP
O	3766	3775	classical	classical	JJ	I-NP
O	3776	3779	HLA	HLA	NN	I-NP
O	3780	3794	classification	classification	NN	I-NP
O	3795	3796	(	(	(	O
O	3796	3799	Fig	Fig	NNP	B-NP
O	3799	3800	.	.	.	O
O	3801	3802	4	4	CD	B-NP
O	3802	3803	,	,	,	O
O	3804	3809	panel	panel	NN	B-NP
O	3810	3811	A	A	NN	I-NP
O	3811	3812	)	)	)	O
O	3813	3814	a	a	DT	B-NP
O	3815	3821	slight	slight	JJ	I-NP
O	3822	3830	improved	improve	VBN	I-NP
O	3831	3835	flow	flow	NN	I-NP
O	3835	3836	-	-	HYPH	I-NP
O	3836	3841	chart	chart	NN	I-NP
O	3842	3843	(	(	(	O
O	3843	3846	Fig	Fig	NNP	B-NP
O	3846	3847	.	.	.	O
O	3848	3849	4	4	CD	B-NP
O	3849	3850	,	,	,	O
O	3851	3856	panel	panel	NN	B-NP
O	3857	3858	B	B	NN	I-NP
O	3858	3859	)	)	)	O
O	3859	3860	:	:	:	O
O	3861	3862	1	1	LS	B-LST
O	3862	3863	)	)	)	O
O	3864	3867	HLA	HLA	NN	B-NP
O	3868	3878	genotyping	genotyping	NN	I-NP
O	3878	3879	:	:	:	O
O	3880	3888	subjects	subject	NNS	B-NP
O	3889	3898	belonging	belong	VBG	B-VP
O	3899	3901	to	to	TO	B-PP
O	3902	3905	the	the	DT	B-NP
O	3906	3909	HLA	HLA	NN	I-NP
O	3910	3914	risk	risk	NN	I-NP
O	3915	3921	groups	group	NNS	I-NP
O	3922	3923	1	1	CD	B-NP
O	3924	3927	and	and	CC	I-NP
O	3928	3929	2	2	CD	I-NP
O	3930	3934	will	will	MD	B-VP
O	3935	3937	be	be	VB	I-VP
O	3938	3948	classified	classify	VBN	I-VP
O	3949	3951	as	as	IN	B-SBAR
O	3952	3954	at	at	IN	B-PP
O	3955	3959	high	high	JJ	B-NP
O	3960	3962	CD	CD	NN	I-NP
O	3963	3967	risk	risk	NN	I-NP
O	3967	3968	;	;	:	O
O	3969	3970	2	2	LS	B-LST
O	3970	3971	)	)	)	O
O	3972	3980	subjects	subject	NNS	B-NP
O	3981	3990	belonging	belong	VBG	B-VP
O	3991	3993	to	to	TO	B-PP
O	3994	3997	the	the	DT	B-NP
O	3998	4001	HLA	HLA	NN	I-NP
O	4002	4006	risk	risk	NN	I-NP
O	4007	4013	groups	group	NNS	I-NP
O	4014	4015	3	3	CD	B-NP
O	4016	4019	and	and	CC	I-NP
O	4020	4021	4	4	CD	I-NP
O	4021	4022	,	,	,	O
O	4023	4027	will	will	MD	B-VP
O	4028	4030	be	be	VB	I-VP
O	4031	4038	further	further	RBR	B-ADJP
O	4039	4051	investigated	investigate	VBN	I-ADJP
O	4052	4055	for	for	IN	B-PP
O	4056	4059	our	our	PRP$	B-NP
O	4060	4064	SNPs	SNP	NNS	I-NP
O	4065	4076	combination	combination	NN	I-NP
O	4077	4078	(	(	(	O
O	4078	4081	LPP	LPP	NN	B-NP
O	4081	4082	,	,	,	O
O	4083	4086	REL	REL	NN	B-NP
O	4086	4087	,	,	,	O
O	4088	4092	RGS1	RGS1	NN	B-NP
O	4092	4093	)	)	)	O
O	4094	4096	in	in	IN	B-SBAR
O	4097	4102	order	order	NN	O
O	4103	4105	to	to	TO	B-VP
O	4106	4115	calculate	calculate	VB	I-VP
O	4116	4121	their	their	PRP$	B-NP
O	4122	4124	BS	BS	NNP	I-NP
O	4125	4126	(	(	(	O
O	4126	4129	Fig	Fig	NNP	B-NP
O	4129	4130	.	.	.	I-NP
O	4131	4132	4	4	CD	I-NP
O	4132	4133	,	,	,	O
O	4134	4139	panel	panel	NN	B-NP
O	4140	4141	B	B	NN	I-NP
O	4141	4142	)	)	)	O
O	4142	4143	.	.	.	O

O	4144	4149	Among	Among	IN	B-PP
O	4150	4155	these	these	DT	B-NP
O	4156	4162	latter	latter	JJ	I-NP
O	4163	4171	subjects	subject	NNS	I-NP
O	4172	4177	those	those	DT	B-NP
O	4178	4182	with	with	IN	B-PP
O	4183	4184	a	a	DT	B-NP
O	4185	4187	BS	BS	NN	I-NP
O	4188	4189	>	>	NN	I-NP
O	4189	4190	=	=	SYM	B-VP
O	4191	4194	the	the	DT	B-NP
O	4195	4201	median	median	JJ	I-NP
O	4202	4207	value	value	NN	I-NP
O	4208	4212	will	will	MD	B-VP
O	4213	4215	be	be	VB	I-VP
O	4216	4226	classified	classify	VBN	I-VP
O	4227	4229	at	at	IN	B-PP
O	4230	4234	high	high	JJ	B-NP
O	4235	4239	risk	risk	NN	I-NP
O	4239	4240	;	;	:	O
O	4241	4242	3	3	LS	B-LST
O	4242	4243	)	)	)	O
O	4244	4252	subjects	subject	NNS	B-NP
O	4253	4262	belonging	belong	VBG	B-VP
O	4263	4265	to	to	TO	B-PP
O	4266	4269	the	the	DT	B-NP
O	4270	4273	HLA	HLA	NN	I-NP
O	4274	4278	risk	risk	NN	I-NP
O	4279	4284	group	group	NN	I-NP
O	4285	4286	5	5	CD	B-NP
O	4287	4291	will	will	MD	B-VP
O	4292	4294	be	be	VB	I-VP
O	4295	4305	considered	consider	VBN	I-VP
O	4306	4308	at	at	IN	B-PP
O	4309	4312	low	low	JJ	B-NP
O	4313	4315	CD	CD	NN	I-NP
O	4316	4320	risk	risk	NN	I-NP
O	4320	4321	.	.	.	O

O	4322	4325	All	All	DT	B-NP
O	4326	4328	CD	CD	NNP	I-NP
O	4329	4338	familials	familial	NNS	I-NP
O	4339	4348	belonging	belong	VBG	B-VP
O	4349	4351	to	to	TO	B-PP
O	4352	4355	the	the	DT	B-NP
O	4356	4361	above	above	RB	I-NP
O	4362	4366	high	high	JJ	I-NP
O	4367	4371	risk	risk	NN	I-NP
O	4372	4378	groups	group	NNS	I-NP
O	4379	4380	(	(	(	O
O	4380	4383	HLA	HLA	NN	B-NP
O	4384	4389	group	group	NN	I-NP
O	4390	4391	1	1	CD	I-NP
O	4391	4392	-	-	HYPH	I-NP
O	4392	4393	2	2	CD	I-NP
O	4394	4397	and	and	CC	I-NP
O	4398	4401	HLA	HLA	NN	I-NP
O	4402	4407	group	group	NN	I-NP
O	4408	4409	3	3	CD	B-NP
O	4409	4410	-	-	HYPH	I-NP
O	4410	4411	4	4	CD	I-NP
O	4412	4416	with	with	IN	B-PP
O	4417	4419	BS	BS	NN	B-NP
O	4420	4421	>	>	SYM	B-NP
O	4421	4422	=	=	SYM	B-VP
O	4423	4429	median	median	NN	B-NP
O	4429	4430	)	)	)	O
O	4431	4435	will	will	MD	B-VP
O	4436	4438	be	be	VB	I-VP
O	4439	4446	undergo	undergo	VB	I-VP
O	4447	4448	a	a	DT	B-NP
O	4449	4455	strict	strict	JJ	I-NP
O	4456	4468	surveillance	surveillance	NN	I-NP
O	4468	4469	.	.	.	O

O	4470	4472	10	10	CD	B-NP
O	4472	4473	.	.	.	I-NP
O	4473	4477	1371	1371	CD	I-NP
O	4477	4478	/	/	SYM	I-NP
O	4478	4485	journal	journal	NN	I-NP
O	4485	4486	.	.	SYM	I-NP
O	4486	4490	pone	pone	NN	I-NP
O	4490	4491	.	.	.	O
O	4491	4498	0026920	0026920	CD	B-NP
O	4498	4499	.	.	.	O
O	4499	4503	g004	g004	CD	B-NP
O	4504	4510	Figure	Figure	NNP	I-NP
O	4511	4512	4	4	CD	I-NP

O	4513	4527	Classification	Classification	NN	B-NP
O	4528	4532	flow	flow	NN	I-NP
O	4532	4533	-	-	HYPH	B-NP
O	4533	4538	chart	chart	NN	I-NP
O	4538	4539	.	.	.	O

O	4540	4542	In	In	IN	B-PP
O	4543	4548	panel	panel	NN	B-NP
O	4549	4550	A	A	NN	I-NP
O	4551	4554	the	the	DT	B-NP
O	4555	4564	classical	classical	JJ	I-NP
O	4565	4568	HLA	HLA	NN	I-NP
O	4568	4569	-	-	HYPH	B-VP
O	4569	4574	based	base	VBN	B-NP
O	4575	4589	classification	classification	NN	I-NP
O	4589	4590	.	.	.	O

O	4591	4593	In	In	IN	B-PP
O	4594	4599	panel	panel	NN	B-NP
O	4600	4601	B	B	NN	I-NP
O	4602	4605	the	the	DT	B-NP
O	4606	4614	proposed	propose	VBN	I-NP
O	4615	4617	BS	BS	NN	I-NP
O	4617	4618	-	-	HYPH	O
O	4618	4623	based	base	VBN	B-NP
O	4624	4638	classification	classification	NN	I-NP
O	4639	4650	considering	consider	VBG	B-VP
O	4651	4654	the	the	DT	B-NP
O	4655	4664	genotypes	genotype	NNS	I-NP
O	4665	4667	of	of	IN	B-PP
O	4668	4671	HLA	HLA	NN	B-NP
O	4672	4676	plus	plus	CC	I-NP
O	4677	4680	LPP	LPP	NN	I-NP
O	4680	4681	,	,	,	I-NP
O	4682	4686	RGS1	RGS1	NN	I-NP
O	4687	4690	and	and	CC	I-NP
O	4691	4694	REL	REL	NN	I-NP
O	4695	4699	SNPs	SNP	NNS	I-NP
O	4699	4700	.	.	.	O

O	4701	4704	One	One	CD	B-NP
O	4705	4707	of	of	IN	B-PP
O	4708	4711	the	the	DT	B-NP
O	4712	4722	limitation	limitation	NN	I-NP
O	4723	4725	of	of	IN	B-PP
O	4726	4729	our	our	PRP$	B-NP
O	4730	4736	cohort	cohort	JJ	I-NP
O	4737	4743	family	family	NN	I-NP
O	4744	4749	study	study	NN	I-NP
O	4750	4755	could	could	MD	B-VP
O	4756	4758	be	be	VB	I-VP
O	4759	4762	the	the	DT	B-NP
O	4763	4769	sample	sample	NN	I-NP
O	4770	4774	size	size	NN	I-NP
O	4774	4775	,	,	,	O
O	4776	4781	which	which	WDT	B-NP
O	4782	4785	may	may	MD	B-VP
O	4786	4790	have	have	VB	I-VP
O	4791	4794	not	not	RB	I-VP
O	4795	4802	allowed	allow	VBN	I-VP
O	4803	4805	to	to	TO	I-VP
O	4806	4813	explore	explore	VB	I-VP
O	4814	4819	genes	gene	NNS	B-NP
O	4820	4822	at	at	IN	B-PP
O	4823	4830	smaller	small	JJR	B-NP
O	4831	4837	effect	effect	NN	I-NP
O	4837	4838	,	,	,	O
O	4839	4841	so	so	RB	O
O	4842	4852	explaining	explain	VBG	B-VP
O	4853	4856	the	the	DT	B-NP
O	4857	4861	lack	lack	NN	I-NP
O	4862	4864	of	of	IN	B-PP
O	4865	4876	association	association	NN	B-NP
O	4877	4884	between	between	IN	B-PP
O	4885	4889	SNPs	SNP	NNS	B-NP
O	4890	4892	in	in	IN	B-PP
O	4893	4898	TAGAP	TAGAP	NN	B-NP
O	4898	4899	,	,	,	O
O	4900	4903	IL2	IL2	NN	B-NP
O	4903	4904	/	/	SYM	B-NP
O	4904	4908	IL21	IL21	NN	I-NP
O	4908	4909	,	,	,	I-NP
O	4910	4915	OLIG3	OLIG3	NN	I-NP
O	4915	4916	,	,	,	I-NP
O	4917	4920	CCR	CCR	NN	I-NP
O	4920	4921	,	,	,	I-NP
O	4922	4927	SH2B3	SH2B3	NN	I-NP
O	4927	4928	,	,	,	I-NP
O	4929	4934	IL12A	IL12A	NN	I-NP
O	4935	4938	and	and	CC	I-NP
O	4939	4944	IL12A	IL12A	NN	I-NP
O	4944	4945	/	/	SYM	B-NP
O	4945	4951	SCHIP1	SCHIP1	NN	B-NP
O	4952	4957	genes	gene	NNS	I-NP
O	4958	4962	with	with	IN	B-PP
O	4963	4965	CD	CD	NN	B-NP
O	4966	4974	although	although	IN	B-SBAR
O	4975	4978	the	the	DT	B-NP
O	4979	4984	trend	trend	NN	I-NP
O	4985	4993	observed	observe	VBN	B-VP
O	4994	4996	in	in	IN	B-PP
O	4997	5005	previous	previous	JJ	B-NP
O	5006	5013	studies	study	NNS	I-NP
O	5014	5016	in	in	IN	B-PP
O	5017	5026	unrelated	unrelated	JJ	B-NP
O	5027	5029	CD	CD	NN	I-NP
O	5030	5038	patients	patient	NNS	I-NP
O	5039	5042	was	be	VBD	B-VP
O	5043	5052	confirmed	confirm	VBN	I-VP
O	5053	5054	[	[	(	O
O	5054	5056	13	13	CD	B-NP
O	5056	5057	]	]	)	O
O	5057	5058	.	.	.	O

O	5059	5061	In	In	IN	B-PP
O	5062	5065	the	the	DT	B-NP
O	5066	5070	main	main	JJ	I-NP
O	5071	5075	time	time	NN	I-NP
O	5076	5079	the	the	DT	B-NP
O	5080	5091	homogeneity	homogeneity	NN	I-NP
O	5092	5094	of	of	IN	B-PP
O	5095	5098	the	the	DT	B-NP
O	5099	5106	genetic	genetic	JJ	I-NP
O	5107	5110	and	and	CC	I-NP
O	5111	5124	environmental	environmental	JJ	I-NP
O	5125	5132	domains	domain	NNS	I-NP
O	5133	5135	in	in	IN	B-PP
O	5136	5139	the	the	DT	B-NP
O	5140	5146	tested	test	VBN	I-NP
O	5147	5155	families	family	NNS	I-NP
O	5156	5162	allows	allow	VBZ	B-VP
O	5163	5165	to	to	TO	I-VP
O	5166	5173	explore	explore	VB	I-VP
O	5174	5178	risk	risk	NN	B-NP
O	5179	5186	factors	factor	NNS	I-NP
O	5187	5193	within	within	IN	B-PP
O	5194	5195	a	a	DT	B-NP
O	5196	5206	controlled	control	VBN	I-NP
O	5207	5213	cohort	cohort	NN	I-NP
O	5213	5214	.	.	.	O

O	5215	5216	A	A	DT	B-NP
O	5217	5223	second	second	JJ	I-NP
O	5224	5229	limit	limit	NN	I-NP
O	5230	5232	of	of	IN	B-PP
O	5233	5236	the	the	DT	B-NP
O	5237	5242	study	study	NN	I-NP
O	5243	5245	is	be	VBZ	B-VP
O	5246	5249	the	the	DT	B-NP
O	5250	5260	relatively	relatively	RB	I-NP
O	5261	5266	short	short	JJ	I-NP
O	5267	5268	(	(	(	O
O	5268	5269	6	6	CD	B-NP
O	5270	5275	years	year	NNS	I-NP
O	5275	5276	)	)	)	O
O	5277	5283	follow	follow	VBP	B-VP
O	5284	5286	up	up	RP	B-PRT
O	5287	5289	of	of	IN	B-PP
O	5290	5293	the	the	DT	B-NP
O	5294	5301	sibship	sibship	NN	I-NP
O	5301	5302	,	,	,	O
O	5303	5308	which	which	WDT	B-NP
O	5309	5314	could	could	MD	B-VP
O	5315	5320	cause	cause	VB	I-VP
O	5321	5323	an	an	DT	B-NP
O	5324	5339	underestimation	underestimation	NN	I-NP
O	5340	5342	of	of	IN	B-PP
O	5343	5346	the	the	DT	B-NP
O	5347	5354	disease	disease	NN	I-NP
O	5355	5366	development	development	NN	I-NP
O	5367	5369	at	at	IN	B-PP
O	5370	5375	later	later	JJ	B-NP
O	5376	5380	ages	age	NNS	I-NP
O	5380	5381	.	.	.	O

O	5382	5385	Our	Our	PRP$	B-NP
O	5386	5389	aim	aim	NN	I-NP
O	5390	5392	is	be	VBZ	B-VP
O	5393	5395	to	to	TO	B-VP
O	5396	5398	go	go	VB	I-VP
O	5399	5401	on	on	RP	B-PRT
O	5402	5406	with	with	IN	B-PP
O	5407	5410	the	the	DT	B-NP
O	5411	5421	monitoring	monitoring	NN	I-NP
O	5422	5424	of	of	IN	B-PP
O	5425	5430	these	these	DT	B-NP
O	5431	5439	families	family	NNS	I-NP
O	5440	5442	in	in	IN	B-PP
O	5443	5446	the	the	DT	B-NP
O	5447	5451	next	next	JJ	I-NP
O	5452	5457	years	year	NNS	I-NP
O	5457	5458	.	.	.	O

O	5459	5461	In	In	IN	B-PP
O	5462	5472	conclusion	conclusion	NN	B-NP
O	5472	5473	,	,	,	O
O	5474	5477	the	the	DT	B-NP
O	5478	5486	estimate	estimate	NN	I-NP
O	5487	5489	of	of	IN	B-PP
O	5490	5493	the	the	DT	B-NP
O	5494	5496	CD	CD	NN	I-NP
O	5497	5501	risk	risk	NN	I-NP
O	5502	5504	by	by	IN	B-PP
O	5505	5508	HLA	HLA	NN	B-NP
O	5508	5509	+	+	SYM	B-NP
O	5509	5513	SNPs	SNP	NNS	I-NP
O	5514	5522	approach	approach	NN	I-NP
O	5522	5523	,	,	,	O
O	5524	5528	even	even	RB	B-SBAR
O	5529	5531	if	if	IN	I-SBAR
O	5532	5535	not	not	RB	O
O	5536	5546	applicable	applicable	JJ	B-ADJP
O	5547	5549	to	to	TO	B-VP
O	5550	5560	prevention	prevention	VB	I-VP
O	5560	5561	,	,	,	O
O	5562	5567	could	could	MD	B-VP
O	5568	5570	be	be	VB	I-VP
O	5571	5572	a	a	DT	B-NP
O	5573	5581	precious	precious	JJ	I-NP
O	5582	5586	tool	tool	NN	I-NP
O	5587	5596	improving	improve	VBG	B-VP
O	5597	5599	CD	CD	NN	B-NP
O	5600	5609	diagnosis	diagnosis	NN	I-NP
O	5610	5617	respect	respect	NN	I-NP
O	5618	5620	to	to	TO	B-PP
O	5621	5624	the	the	DT	B-NP
O	5625	5629	only	only	JJ	I-NP
O	5630	5633	HLA	HLA	NN	I-NP
O	5634	5635	(	(	(	O
O	5635	5638	NPV	NPV	NN	B-NP
O	5638	5639	:	:	:	O
O	5640	5642	95	95	CD	B-NP
O	5642	5643	%	%	NN	I-NP
O	5644	5646	vs	vs	IN	B-PP
O	5647	5649	91	91	CD	B-NP
O	5649	5650	%	%	NN	I-NP
O	5650	5651	,	,	,	O
O	5652	5655	and	and	CC	O
O	5656	5658	DS	DS	NN	B-NP
O	5658	5659	:	:	:	O
O	5660	5662	79	79	CD	B-NP
O	5662	5663	%	%	NN	I-NP
O	5664	5666	vs	vs	IN	B-PP
O	5667	5669	45	45	CD	B-NP
O	5669	5670	%	%	NN	I-NP
O	5670	5671	)	)	)	O
O	5671	5672	,	,	,	O
O	5673	5675	in	in	IN	B-PP
O	5676	5679	the	the	DT	B-NP
O	5680	5686	cohort	cohort	NN	I-NP
O	5687	5689	of	of	IN	B-PP
O	5690	5695	first	first	JJ	B-NP
O	5696	5702	degree	degree	NN	I-NP
O	5703	5712	relatives	relative	NNS	I-NP
O	5712	5713	.	.	.	O

O	5714	5716	In	In	IN	B-PP
O	5717	5721	fact	fact	NN	B-NP
O	5722	5724	in	in	IN	B-PP
O	5725	5733	clinical	clinical	JJ	B-NP
O	5734	5742	practice	practice	NN	I-NP
O	5743	5746	the	the	DT	B-NP
O	5747	5754	absence	absence	NN	I-NP
O	5755	5757	of	of	IN	B-PP
O	5758	5761	HLA	HLA	NN	B-NP
O	5762	5766	risk	risk	NN	I-NP
O	5767	5773	groups	group	NNS	I-NP
O	5774	5775	1	1	CD	B-NP
O	5776	5778	or	or	CC	I-NP
O	5779	5780	2	2	CD	I-NP
O	5780	5781	,	,	,	O
O	5782	5788	allows	allow	VBZ	B-VP
O	5789	5791	to	to	TO	I-VP
O	5792	5799	exclude	exclude	VB	I-VP
O	5800	5803	the	the	DT	B-NP
O	5804	5811	disease	disease	NN	I-NP
O	5812	5816	with	with	IN	B-PP
O	5817	5821	high	high	JJ	B-NP
O	5822	5833	probability	probability	NN	I-NP
O	5833	5834	,	,	,	O
O	5835	5840	while	while	IN	B-SBAR
O	5841	5848	testing	test	VBG	B-VP
O	5849	5852	the	the	DT	B-NP
O	5853	5858	three	three	CD	I-NP
O	5859	5863	SNPs	SNP	NNS	I-NP
O	5864	5866	in	in	IN	B-PP
O	5867	5870	HLA	HLA	NN	B-NP
O	5871	5877	groups	group	NNS	I-NP
O	5878	5879	3	3	CD	B-NP
O	5880	5882	or	or	CC	I-NP
O	5883	5884	4	4	CD	I-NP
O	5885	5890	could	could	MD	B-VP
O	5891	5900	represent	represent	VB	I-VP
O	5901	5902	a	a	DT	B-NP
O	5903	5910	further	further	JJ	I-NP
O	5911	5915	tool	tool	NN	I-NP
O	5916	5918	to	to	TO	B-VP
O	5919	5927	identify	identify	VB	I-VP
O	5928	5932	less	less	RBR	B-NP
O	5933	5941	frequent	frequent	JJ	I-NP
O	5942	5944	CD	CD	NN	I-NP
O	5945	5950	cases	case	NNS	I-NP
O	5950	5951	.	.	.	O

O	5952	5954	So	So	RB	B-ADVP
O	5954	5955	,	,	,	O
O	5956	5958	an	an	DT	B-NP
O	5959	5965	infant	infant	NN	I-NP
O	5966	5970	with	with	IN	B-PP
O	5971	5975	high	high	JJ	B-NP
O	5976	5979	HLA	HLA	NN	I-NP
O	5979	5980	+	+	SYM	B-NP
O	5980	5984	SNPs	SNP	NNS	I-NP
O	5985	5990	score	score	VBP	B-VP
O	5991	5995	even	even	RB	B-SBAR
O	5996	5998	if	if	IN	I-SBAR
O	5999	6008	belonging	belong	VBG	B-VP
O	6009	6011	to	to	TO	B-PP
O	6012	6015	HLA	HLA	NN	B-NP
O	6016	6019	low	low	JJ	I-NP
O	6020	6024	risk	risk	NN	I-NP
O	6025	6031	groups	group	NNS	I-NP
O	6031	6032	,	,	,	O
O	6033	6038	shall	shall	MD	B-VP
O	6039	6046	undergo	undergo	VB	I-VP
O	6047	6048	a	a	DT	B-NP
O	6049	6055	simple	simple	JJ	I-NP
O	6056	6068	surveillance	surveillance	NN	I-NP
O	6069	6075	system	system	NN	I-NP
O	6076	6078	to	to	TO	B-VP
O	6079	6084	allow	allow	VB	I-VP
O	6085	6091	proper	proper	JJ	B-NP
O	6092	6101	diagnosis	diagnosis	NN	I-NP
O	6102	6105	and	and	CC	I-NP
O	6106	6115	treatment	treatment	NN	I-NP
O	6116	6122	before	before	IN	B-PP
O	6123	6126	the	the	DT	B-NP
O	6127	6131	full	full	JJ	I-NP
O	6132	6136	blow	blow	NN	I-NP
O	6137	6144	disease	disease	NN	I-NP
O	6145	6152	appears	appear	VBZ	B-VP
O	6152	6153	.	.	.	O

